Idiopathic Pulmonary Fibrosis Treatment Market – Size, Therapeutics, Growth Opportunity, Regional Trends, Research Updates, Industry Share and Technology Development By Key Players, Forecast to 2025

Idiopathic Pulmonary Fibrosis Treatment Market – Size, Therapeutics, Growth Opportunity, Regional Trends, Research Updates, Industry Share and Technology Development By Key Players, Forecast to 2025

“Idiopathic Pulmonary Fibrosis Treatment Market”
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Research by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2025

Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases.

Market Overview

The high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment. The Global Idiopathic Pulmonary Fibrosis Treatment Market is expected to register a CAGR of 12.3% during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018.

The global IPF treatment market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in September 2018, FibroGen, Inc. announced that the grant of Fast Track designation by US Food and Drug Administration (FDA) for the company’s anti-CTGF antibody, Pamrevlumab, for the treatment of patients with IPF.

Avail FREE Sample Report at: https://www.marketresearchfuture.com/sample_request/8109

Additionally, rising prevalence rates of lung diseases coupled with increasing geriatric population is anticipated to fuel the market growth. For instance, according to the Office for National Statistics in 2017, approximately 18% and 2.4% of the total UK population was aged over 65 years and 85 years, respectively. On the other hand, the high cost of surgery is projected to hamper the growth of the market during the assessment period.

Key Players

“Idiopathic Pulmonary Fibrosis (IPF) Treatment Market” Research report provide valuable insight with following companies, which includes – Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibrogen, Inc., Cipla, Merck & Co., Inc., Prometic Life Sciences Inc., and others.

Chapter 9. Company Profile

9.1 Biogen

9.1.1 Company Overview

9.1.2 Product Type Overview

9.1.3 Financials Overview

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.2 Boehringer Ingelheim GMBH

9.2.1 Company Overview

9.2.2 Product Type Overview

9.2.3 Financial Overview

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.3 Bristol-Myers Squibb Company

9.3.1 Company Overview

9.3.2 Product Type Overview

9.3.3 Financial Overview

9.3.4 Key Development

9.3.5 SWOT Analysis

9.4 Cipla

9.4.1 Company Overview

9.4.2 Product Type Overview

And Many More.

Segmentation

The global IPF treatment market has been segmented based on treatment.

The market, based on treatment, has been further divided into drug class, oxygen therapy, lung transplant, and others. The drug class segment is likely to hold a major share in the market due to the increasing adoption of the drugs for the treatment of IPF and wider preferability. The oxygen therapy segment is predicted to be the fastest growing due to the increasing inclination of medical professionals towards this therapy for the treatment of IPF.

IPF is a lung disease which causes the tissue in your lungs to become stiff. The global IPF treatment market is driven by factors such as increasing cases of IPF and growing demand for minimally invasive procedures to diagnose and treat different chronic diseases. For instance, FibroGen, Inc. announced that the grant of Fast Track designation by US Food and Drug Administration (FDA) for the company’s anti-CTGF antibody, Pamrevlumab, for the treatment of patients with IPF.

Browse complete Premium Research Report along with TOC, List of Figures and Tables at https://www.marketresearchfuture.com/reports/stereotactic-surgery-devices-market-6791

Intended Audience

  • Research and development (r&d) companies
  • Medical device companies
  • Government research institutes
  • Academic institutes and universities
  • Venture capitalists

Global Idiopathic Pulmonary Fibrosis Treatment Market, by Region:

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The IPF treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European IPF treatment market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.

The IPF treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The IPF treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Get an Amazing discount on this Report at: https://www.marketresearchfuture.com/check-discount/8109

Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

About Market Research Future: we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/idiopathic-pulmonary-fibrosis-treatment-market-8109